# A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for

Source: https://onco.cc/trials/nct05024097/  
OnCo record `nct05024097` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zimberelimab in colorectal cancer, run by Weill Medical College of Cornell University, now recruiting.

## Summary

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. is a phase 2, interventional study registered as NCT05024097 by Weill Medical College of Cornell University, with a registry enrolment figure of 43 participants, started 2022-03-31 and due to reach its primary completion in 2026-12. Interventions recorded: Etrumadenant (AB928); Radiation therapy; FOLFOX regimen; Zimberelimab (AB122). Conditions listed: Rectal Cancer. Primary outcome: Number of treated patients who achieve complete pathologic response. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of adenocarcinoma of the rectum". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANTHER
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05024097
- Phase: 2
- Setting: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
- Sponsor: Weill Medical College of Cornell University
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT05024097: https://clinicaltrials.gov/study/NCT05024097

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05024097.json